{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-002694","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.486305+00:00","generated_at":"2026-06-29T11:19:48.001094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data","bullets":["Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).","Cash and equivalents $67M at June 30, 2021, up from $58.2M at March 31; runway to mid 2023.","CM-101 Phase 2a SPRING (PSC) and SPLASH (liver fibrosis) enrolling; data expected in 1H/2H 2022.","Expanded partnership with AGC Biologics to manufacture CM-101 for pivotal studies and launch readiness.","Plan to initiate Phase 2 trial in Systemic Sclerosis in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-002694","json":"https://secwatch.observer/filing/0001178913-21-002694.json","markdown":"https://secwatch.observer/filing/0001178913-21-002694.md","text":"https://secwatch.observer/filing/0001178913-21-002694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/0001178913-21-002694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/zk2126454.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:19:48.001094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}